Loading page…

Report overview

The report describes Hyloris's 2022 performance as a specialty biopharma company with consolidated revenues of 2,951 € thousand and a workforce of 37 people. Its initial ESG roadmap maps the business to four UN Sustainable Development Goals and organizes actions around health and well-being, environmental sustainability and responsible leadership. The report highlights that one of eight board members was a woman and sets a goal for increased board gender diversity by 2026.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language
Pages
File size

Standards & Assurance

Assurance

Level
Standard
Scope
Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board
Women in management

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services